Patents by Inventor Stephen F. Carroll
Stephen F. Carroll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6146631Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.Type: GrantFiled: April 15, 1997Date of Patent: November 14, 2000Assignee: Xoma CorporationInventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
-
Patent number: 6146850Abstract: The present invention provides purified proteins that contain gelonin amino acid sequences that have enzymatic activity.Type: GrantFiled: August 18, 1998Date of Patent: November 14, 2000Assignee: Xoma CorporationInventors: Marc D. Better, Stephen F. Carroll
-
Patent number: 6093573Abstract: The present invention provides a crystallized Bactericidal Permeability-Increasing (BPI) protein; methods for x-ray diffraction analysis to provide x-ray diffraction patterns of sufficiently high resolution for three-dimensional structure determination of the protein, as well as methods for rational drug design, based on using amino acid sequence data and/or x-ray crystallography data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms; and atomic coordinates are provided yielding structural information on the lipid binding and lipid transport protein family that includes BPI, LBP, CETP and PLTP.Type: GrantFiled: June 20, 1997Date of Patent: July 25, 2000Assignees: XOMA, The Regents of the University of CaliforniaInventors: Lesa J. Beamer, Stephen F. Carroll, David Eisenberg
-
Patent number: 6087126Abstract: Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.Type: GrantFiled: June 18, 1999Date of Patent: July 11, 2000Assignee: XOMA CorporationInventors: Arnold Horwitz, Stephen F. Carroll, David Burke
-
Patent number: 5990082Abstract: Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin.Type: GrantFiled: October 22, 1997Date of Patent: November 23, 1999Assignee: Xoma CorporationInventors: Russell L. Dedrick, Stephen F. Carroll
-
Patent number: 5837491Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.Type: GrantFiled: May 13, 1996Date of Patent: November 17, 1998Assignee: Xoma CorporationInventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
-
Patent number: 5756699Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.Type: GrantFiled: June 7, 1995Date of Patent: May 26, 1998Assignee: Xoma CorporationInventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
-
Patent number: 5744580Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.Type: GrantFiled: June 7, 1995Date of Patent: April 28, 1998Assignee: Xoma CorporationInventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
-
Patent number: 5621083Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.Type: GrantFiled: April 18, 1995Date of Patent: April 15, 1997Assignee: XOMA CorporationInventors: Marc D. Better, Stephen F. Carroll, Gary M. Studnicka
-
Patent number: 5484705Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.Type: GrantFiled: January 24, 1994Date of Patent: January 16, 1996Assignee: XOMA CorporationInventors: Mark L. White, Stephen F. Carroll, Jeremy K. Ma
-
Patent number: 5466580Abstract: The present invention provides a method for quantifying the presence of extracellular BPI in body fluids including blood in a subject comprising conducting a BPI immunoassay on plasma obtained from said subject.Type: GrantFiled: September 22, 1993Date of Patent: November 14, 1995Assignee: XOMA CorporationInventors: Mark L. White, Stephen F. Carroll, Jeremy K. Ma
-
Patent number: 5466581Abstract: The present invention provides an immunoassay method for screening for gram negative sepsis in a subject, in which the concentration of extracellular BPI in a plasma sample from the subject is determined and compared with a standard concentration of BPI indicative of gram negative sepsis.Type: GrantFiled: December 29, 1993Date of Patent: November 14, 1995Assignee: XOMA CorporationInventors: Mark L. White, Stephen F. Carroll, Jeremy K.-k. Ma
-
Patent number: 5183904Abstract: Novel compounds and methods for the formation of disulfide linkages are presented. The novel compounds employed are substituted 2-iminothiolane hydrohalide linking agents of the following formula (I): ##STR1## wherein, X is halogen;R.sub.1 is COOR.sub.5 ; halogen; nitro; unsubstituted or halogenated C.sub.1-8 alkyl; unsubstituted or halogenated C.sub.1-8 alkoxy; unsubstituted or halogenated C.sub.2-8 alkenyl; unsubstituted or halogenated C.sub.2-8 alkynyl; unsubstituted C.sub.3-8 cycloalkyl; unsubstituted aryl; aryl substituted with 1 to 3 substituents selected from halogen, amino, unsubstituted or halogenated C.sub.1-8 alkyl, or unsubstituted or halogenated C.sub.1-8 alkoxy; unsubstituted heterocycle; or heterocycle substituted with 1 to 3 substituents selected from amino, halogen, unsubstituted or halogenated C.sub.1-8 alkyl, or unsubstituted or halogenated C.sub.1-8 alkoxy;each of R.sub.2, R.sub.3 and R.sub.4 is independently hydrogen or selected from the values of R.sub.1 ; orR.sub.1 and R.sub.Type: GrantFiled: November 20, 1991Date of Patent: February 2, 1993Assignee: Xoma CorporationInventors: Stephen F. Carroll, Dane A. Goff
-
Patent number: 5093475Abstract: Novel compounds and methods for the formation of disulfide linkages are presented. The novel compounds employed are substituted 2-iminothiolane hydrohalide linking agents of the following formula (I): ##STR1## wherein, X is halogen;R.sub.1 is COOR.sub.5 ; halogen; nitro; unsubstituted or halogenated C.sub.1-8 alkyl; unsubstituted or halogenated C.sub.1-8 alkoxy; unsubstituted or halogenated C.sub.2-8 alkenyl; unsubstituted or halogenated C.sub.2-8 alkynyl; unsubstituted C.sub.3-8 cycloalkyl; unsubstituted aryl; aryl substituted with 1 to 3 substituents selected from halogen, amino, unsubstituted or halogenated C.sub.1-8 alkyl, or unsubstituted or halogenated C.sub.1-8 alkoxy; unsubstituted heterocycle; or heterocycle substituted with 1 to 3 substituents selected from amino, halogen, unsubstituted or halogenated C.sub.1-8 alkyl, or unsubstituted or halogenated C.sub.1-8 alkoxy;each of R.sub.2, R.sub.3 and R.sub.4 is independently hydrogen or selected from the values of R.sub.1 ; orR.sub.1 and R.sub.Type: GrantFiled: December 21, 1989Date of Patent: March 3, 1992Assignee: Xoma CorporationInventors: Stephen F. Carroll, Dane A. Goff
-
Patent number: 4709017Abstract: Diphtheria toxin, fragment A, which has been modified by the deletion of Glu-148 or the substitutions of Glu-148 with Asp is catalytically inactive and immunologically cross-reactive with naturally occurring diphtheria toxin, fragment A. The modified diphtheria toxin is compounded with a pharmacologically suitable vehicle to form a vaccine that is innoculated into a mammal to generate immunological protection against diphtheria toxin. The modified diphtheria toxin is produced by a cell that includes a vector having DNA encoding the non-toxic protein and regulatory DNA capable of effecting its expression.Type: GrantFiled: June 7, 1985Date of Patent: November 24, 1987Assignee: President and Fellows of Harvard CollegeInventors: R. John Collier, Stephen F. Carroll